1. Home
  2. CRGO vs ACET Comparison

CRGO vs ACET Comparison

Compare CRGO & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freightos Limited Ordinary shares

CRGO

Freightos Limited Ordinary shares

HOLD

Current Price

$1.34

Market Cap

66.7M

Sector

Finance

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.26

Market Cap

79.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRGO
ACET
Founded
2012
1947
Country
Spain
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.7M
79.9M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
CRGO
ACET
Price
$1.34
$8.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$2.40
$48.33
AVG Volume (30 Days)
37.9K
83.8K
Earning Date
05-26-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.61
N/A
Revenue Next Year
$16.85
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.14
$0.46
52 Week High
$4.24
$9.84

Technical Indicators

Market Signals
Indicator
CRGO
ACET
Relative Strength Index (RSI) 53.71 46.13
Support Level $1.17 $7.45
Resistance Level $1.43 $8.68
Average True Range (ATR) 0.06 0.52
MACD 0.02 -0.06
Stochastic Oscillator 78.85 31.47

Price Performance

Historical Comparison
CRGO
ACET

About CRGO Freightos Limited Ordinary shares

Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters, thousands of forwarders, and dozens of airlines and ocean carriers. The company operates in two segments: the Platform segment and the Solutions segment. The majority of the revenue is derived from the Solutions segment, which provides software tools and data to help industry participants automate their pricing, sales, and procurement processes. Geographically, it generates the maximum revenue from Europe, and the rest from the United States, Hong Kong and Others.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: